Aflibercept（Cat No.:I042679）is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). By binding to these growth factors, it inhibits their interaction with natural VEGF receptors, thereby reducing abnormal blood vessel growth and leakage. Aflibercept is primarily used in the treatment of retinal diseases like age-related macular degeneration (AMD) and diabetic macular edema (DME), as well as certain cancers, including colorectal cancer. It helps control pathological angiogenesis, improving vision and limiting tumor growth by inhibiting angiogenesis.
